Peak Retirement Planning Inc. Makes New $1.06 Million Investment in Insulet Co. (NASDAQ:PODD)

Peak Retirement Planning Inc. purchased a new position in Insulet Co. (NASDAQ:PODD - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 4,070 shares of the medical instruments supplier's stock, valued at approximately $1,063,000.

Several other institutional investors and hedge funds have also made changes to their positions in PODD. SBI Securities Co. Ltd. acquired a new stake in shares of Insulet during the 4th quarter valued at about $36,000. Itau Unibanco Holding S.A. acquired a new stake in shares of Insulet during the fourth quarter worth about $42,000. SRS Capital Advisors Inc. boosted its stake in shares of Insulet by 43.1% in the 4th quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier's stock valued at $49,000 after buying an additional 56 shares during the period. Assetmark Inc. lifted its position in shares of Insulet by 1,447.1% during the 4th quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier's stock worth $69,000 after purchasing an additional 246 shares during the last quarter. Finally, Blue Trust Inc. raised its position in shares of Insulet by 117.3% during the 4th quarter. Blue Trust Inc. now owns 276 shares of the medical instruments supplier's stock worth $72,000 after acquiring an additional 149 shares in the last quarter.

Insider Activity at Insulet

In related news, Director Wayne A.I. Frederick sold 1,825 shares of the company's stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total value of $501,875.00. Following the sale, the director now owns 3,231 shares of the company's stock, valued at $888,525. The trade was a 36.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP John W. Kapples sold 5,278 shares of the stock in a transaction that occurred on Wednesday, May 14th. The stock was sold at an average price of $318.47, for a total value of $1,680,884.66. Following the completion of the transaction, the senior vice president now directly owns 23,180 shares of the company's stock, valued at approximately $7,382,134.60. The trade was a 18.55% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.39% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research analysts have commented on PODD shares. Wolfe Research upgraded shares of Insulet from a "peer perform" rating to an "outperform" rating and set a $350.00 price objective on the stock in a research note on Tuesday, May 13th. Raymond James reissued an "outperform" rating and set a $360.00 price target (up previously from $328.00) on shares of Insulet in a research note on Tuesday. Stifel Nicolaus upped their price objective on Insulet from $245.00 to $293.00 and gave the company a "hold" rating in a research report on Friday, February 21st. Citigroup reaffirmed a "buy" rating and issued a $380.00 target price (up from $320.00) on shares of Insulet in a research report on Thursday, May 22nd. Finally, Canaccord Genuity Group boosted their target price on Insulet from $304.00 to $324.00 and gave the stock a "buy" rating in a report on Friday, February 21st. Four analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $309.88.

Insulet Price Performance

PODD stock traded up $0.42 on Thursday, hitting $323.97. 181,908 shares of the company's stock traded hands, compared to its average volume of 788,269. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. Insulet Co. has a 1-year low of $171.61 and a 1-year high of $329.33. The stock has a market cap of $22.80 billion, a price-to-earnings ratio of 55.95, a P/E/G ratio of 3.62 and a beta of 1.26. The stock has a fifty day moving average of $274.57 and a 200-day moving average of $271.02.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 EPS for the quarter, beating the consensus estimate of $0.81 by $0.21. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The business had revenue of $569.00 million during the quarter, compared to analysts' expectations of $543.20 million. During the same quarter in the previous year, the business posted $0.73 EPS. The firm's quarterly revenue was up 28.8% compared to the same quarter last year. On average, analysts forecast that Insulet Co. will post 3.92 EPS for the current fiscal year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.